[Kangchen Pharmaceutical: The first subject has been enrolled in the phase II clinical study of KC1086 combined with fulvestrant] On November 11, Kangchen Pharmaceutical (603590.SH) announced that the company's independently developed KC1086 tablets have successfully completed the first subject of the "Phase II clinical study of KC1086 combined with fulvestrant in the treatment of HR+/HER2- locally advanced or metastatic breast cancer". KC1086 is a Class 1 innovative chemical drug independently developed by the company. It is a powerful KAT6/7 dual-target small molecule inhibitor. It has launched Phase I clinical trials in August 2025 and has received tacit approval from the U.S. FDA for new drug clinical research. It has become the world's first KAT6/7 small molecule inhibitor to enter the clinical development stage. This research and development progress will not have a significant impact on the company's recent performance.